Soluble HLA in saliva of patients with autoimmune rheumatic diseases

被引:9
|
作者
Adamashvili, I
Pressly, T
Gebel, H
Milford, E
Wolf, R
Mancini, M
Sittg, K
Ghali, GE
Hall, V
McDonald, JC
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Surg, Shreveport, LA 71130 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Ctr Excellence Arthritis & Rheumatol, Shreveport, LA 71130 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Renal Transplantat & Tissue Typing Lab, Cambridge, MA 02138 USA
关键词
major histocompatibility complex; enzyme-linked immunosorbent assay; autoimmune rheumatic diseases;
D O I
10.1007/s00296-002-0173-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The limited number of studies addressing the presence of soluble human leukocyte antigen (HLA) in body fluids such as tears, urine, sweat, and saliva are restricted to healthy subjects. In this study, we applied solid-phase enzyme-linked immunoassay to quantify soluble HLA class I (sHLA-I) and class II (sHLA-II) molecules in saliva and in selected serum samples obtained from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren's syndrome (SS). Results: While saliva from normal subjects (n = 35) contained levels of sHLA-I that were undetectable (n = 7) or ranged from 9 ng/ml to 70 ng/ml (30 +/- 3.7 ng/ml, n = 28), sHLA-I among 38 patients with moderately active RA (n = 24) or SLE (n = 14) were significantly elevated (222 +/- 81.4 ng/ml and 120 +/- 27.3 ng/ml, respectively, P<0.0001). Intriguingly, sHLA-I levels were even higher in patients whose disease was regarded as active. Specifically, sHLA-I averaged 683 1189 ng/ml in patients with active RA (n = 13) and 230 +/- 24.5 ng/ml in patients with active SLE (n = 7). This was significantly higher than in patients with milder forms of these diseases (P<0.0001). All five subjects with SS had severe disease with high levels of sHLA-I (mean 486 +/- 86 ng/ml). The concentrations of saliva sHLA-II in the disease groups studied were comparable with levels found in normal controls. The sHLA-I in severe and mild states was investigated in purified serum and saliva from a patient with SS. While 44-kDa fragments of serum HLA-I were detectable in severe SS, they were undetectable in saliva HLA at any time; 35-37-kDa fragments of serum or saliva HLA-I were detected during both mild and severe disease. Interestingly, the 39-kDa fragment was detected in both body fluids during severe but not mild forms of SS. Similarly, the isoforms with the molecular masses 39 kDa and 44 kDa were mainly identified in the purified material obtained from serum of SLE patients. Conclusions: Collectively, our data suggest that the measurement of soluble HLA in body fluids can be of both diagnostic and prognostic value in the assessment of patients with autoimmune rheumatic disorders. The mechanism by which sHLA enters saliva is unclear, but they probably are not acquired from serum.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [1] Soluble HLA in saliva of patients with autoimmune rheumatic diseases
    Irena Adamashvili
    Thomas Pressly
    Howard Gebel
    Edgar Milford
    Robert Wolf
    Mary Mancini
    Kevin Sittg
    G. Ghali
    Vicky Hall
    John C. McDonald
    [J]. Rheumatology International, 2002, 22 : 71 - 76
  • [2] Soluble HLA-G in pregnancies complicated by autoimmune rheumatic diseases
    Beneventi, Fausta
    Badulli, Carla
    Locatelli, Elena
    Caporali, Roberto
    Ramoni, Veronique
    Cavagnoli, Chiara
    Simonetta, Margherita
    Garbin, Giulia
    Tinelli, Carmine
    Alpini, Claudia
    Montecucco, CarloMaurizio
    Martinetti, Miryam
    Spinillo, Arsenio
    [J]. JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2015, 110 : 67 - 73
  • [3] Serum soluble Fas levels in patients with autoimmune rheumatic diseases
    Sahin, M.
    Aydintug, O.
    Tunc, S. E.
    Tutkak, H.
    Naziroglu, M.
    [J]. CLINICAL BIOCHEMISTRY, 2007, 40 (1-2) : 6 - 10
  • [4] SOLUBLE HLA IN AUTOIMMUNE-DISEASES
    ADAMSHVILI, IM
    MCDONALD, JC
    MILFORD, EL
    GELDER, FB
    FRASER, PA
    [J]. HUMAN IMMUNOLOGY, 1993, 37 : 51 - 51
  • [5] Soluble HLA-I in rheumatic diseases
    Wolf, RE
    Adamashvili, IM
    Gelder, FB
    Hall, VC
    Fraser, PA
    McDonald, JC
    [J]. HUMAN IMMUNOLOGY, 1998, 59 (10) : 644 - 649
  • [6] HLA CLASS-III MOLECULES AND AUTOIMMUNE RHEUMATIC DISEASES
    ARNETT, FC
    MOULDS, JM
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1991, 9 (03) : 289 - 296
  • [7] Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases
    Sfikakis, PP
    Tsokos, GC
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (03) : 241 - 246
  • [8] Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
    Manfredi, Mariangela
    Van Hoovels, Lieve
    Benucci, Maurizio
    De Luca, Riccardo
    Coccia, Carmela
    Bernardini, Pamela
    Russo, Edda
    Amedei, Amedeo
    Guiducci, Serena
    Grossi, Valentina
    Bossuyt, Xavier
    Perricone, Carlo
    Infantino, Maria
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (04):
  • [9] Autoimmune Rheumatic Diseases 1 Clinical aspects of autoimmune rheumatic diseases
    Goldblatt, Fiona
    O'Neill, Sean G.
    [J]. LANCET, 2013, 382 (9894): : 797 - 808
  • [10] Vaccination of patients with autoimmune inflammatory rheumatic diseases
    Johanna Westra
    Christien Rondaan
    Sander van Assen
    Marc Bijl
    [J]. Nature Reviews Rheumatology, 2015, 11 : 135 - 145